Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Abstract Text:

Peter Hillmen,Petra Muus,Ulrich ,Antonio M Risitano, Schubert,Lucio Luzzatto,Hubert Schrezenmeier,Jeffrey Szer,Robert A Brodsky,Anita Hill,Gerard ,Monica Bessler,Scott A Rollins,Leonard Bell,Russell P Rother,Neal S Young,Peter Hillmen,Petra Muus,Ulrich ,Antonio M Risitano, Schubert,Lucio Luzzatto,Hubert Schrezenmeier,Jeffrey Szer,Robert A Brodsky,Anita Hill,Gerard ,Monica Bessler,Scott A Rollins,Leonard Bell,Russell P Rother,Neal S Young,Peter Hillmen,Petra Muus,Ulrich ,Antonio M Risitano, Schubert,Lucio Luzzatto,Hubert Schrezenmeier,Jeffrey Szer,Robert A Brodsky,Anita Hill,Gerard ,Monica Bessler,Scott A Rollins,Leonard Bell,Russell P Rother,Neal S Young,

Hemolysis and hemoglobinemia contribute to serious clinical sequelae in hemolytic disorders. In paroxysmal nocturnal hemoglobinuria (PNH) patients, hemolysis can contribute to thromboembolism (TE), the most feared complication in PNH, and the leading cause of disease-related deaths. We evaluated whether long-term treatment with the complement inhibitor eculizumab reduces the rate of TE in patients with PNH. Clinical trial participants included all patients in the 3 eculizumab PNH clinical studies, which recruited patients between 2002 and 2005 (n = 195); patients from these studies continued treatment in the current multinational open-label extension study. Thromboembolism rate with eculizumab treatment was compared with the pretreatment rate in the same patients. The TE event rate with eculizumab treatment was 1.07 events/100 patient-years compared with 7.37 events/100 patient-years (P < .001) prior to eculizumab treatment (relative reduction, 85%; absolute reduction, 6.3 TE events/100 patient-years). With equalization of the duration of exposure before and during treatment for each patient, TE events were reduced from 39 events before eculizumab to 3 events during eculizumab (P < .001). The TE event rate in antithrombotic-treated patients (n = 103) was reduced from 10.61 to 0.62 events/100 patient-years with eculizumab treatment (P < .001). These results show that eculizumab treatment reduces the risk of clinical thromboembolism in patients with PNH. This study is registered at http://clinicaltrials.gov (study ID no. NCT00122317).

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Publishing Authors By Initials

P Hillmen,P Muus,U ,AM Risitano,J Schubert,L Luzzatto,H Schrezenmeier,J Szer,RA Brodsky,A Hill,G ,M Bessler,SA Rollins,L Bell,RP Rother,NS Young,P Hillmen,P Muus,U ,AM Risitano,J Schubert,L Luzzatto,H Schrezenmeier,J Szer,RA Brodsky,A Hill,G ,M Bessler,SA Rollins,L Bell,RP Rother,NS Young,P Hillmen,P Muus,U ,AM Risitano,J Schubert,L Luzzatto,H Schrezenmeier,J Szer,RA Brodsky,A Hill,G ,M Bessler,SA Rollins,L Bell,RP Rother,NS Young,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Blood

VOLUME: 110

Page Numbers: 4123-8

Journal Abbreviation: Blood

ISSN: 0006-4971

DAY: 16

MONTH: 08

YEAR: 2007

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7603509

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

AFFILIATION:

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Blood

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria Related Publications

• A comparison of neural differentiation and retinal transplantation with bone marrow-derived cells and retinal progenitor cells.
• A national perspective of surgery in children with cerebral palsy.
• Adapting to artificial gravity (AG) at high rotational speeds.
• Anthrax toxin receptor 2-dependent lethal toxin killing in vivo.
• Assembly of multilayer films incorporating a viral protein cage architecture.
• Combating the epidemic of obesity and cardiovascular disease: perspectives from school-aged children.
• Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report.
• Correlation of scrotal circumference and age in American Brahman bulls.
• Death by managed care-denial of hospitalization for headache.
• Dehiscent high jugular bulb: a pitfall in middle ear surgery.
• Developmental origins of obesity: a sympathoadrenal perspective.
• Dorsal cochlear nucleus response properties following acoustic trauma: response maps and spontaneous activity.
• Endoscopic management of hydrocephalus secondary to tumors of the posterior third ventricle.
• Examination of the food and nutrient content of school lunch menus of two school districts in Mississippi.
• Failure of gonadotropin-releasing hormone or human chorionic gonadotropin to enhance the fertility of repeat-breeder cows when administered at the time of insemination.
• Implementation of a cardiovascular disease prevention program among school-aged children: a pilot study.
• Interplay of circadian clocks and metabolic rhythms.
• Large recursive partitioning analysis of complex disease pharmacogenetic studies. II. Statistical considerations.
• Longer fixation duration while viewing face images.
• Loss of O-antigen increases cell shape abnormalities in penicillin-binding protein mutants of Escherichia coli.
• Molecular and statistical tools for circadian transcript profiling.
• Objectively measured physical activity in sixth-grade girls.
• Primate molecular divergence dates.
• Protein farnesyltransferase inhibitors and progeria.
• Simultaneous and concurrent polydrug use of alcohol and prescription drugs: prevalence, correlates, and consequences.
• Social effectiveness therapy for children: five years later.
• Story recall and narrative coherence of high-functioning children with autism spectrum disorders.
• Structure of the MAST with an Australian sample of alcoholics.
• Synthesis of (2S,4S)- and (2S,4R)-5-fluoroleucine and (2S,4S)-[5,5-2H2]-5-fluoroleucine.
• Vestibular evoked myogenic potentials in acute acoustic trauma.